КАРРИ Марк Дж. (US),МАХАДЖАН-МИКЛОС Шалин (US),НОРМАН Теа (US),МИЛН Тодд Дж. (US)
申请号：
RU2014153593
公开号：
RU2014153593A
申请日:
2014.12.26
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A peptide consisting of the amino acid sequence CysCysGluTyrCysCysAsnProAlaCysThrGlyCysTyr, where disulfide bonds are present between Cys-Cys, Cys-Cys and Cys-Cys, or a pharmaceutically acceptable salt thereof. The peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide increases the activity of the guanylate cyclase receptor C.3. A pharmaceutical composition comprising the peptide of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or medium. The pharmaceutical composition of claim 3 for use in enhancing intestinal motility in a patient. The pharmaceutical composition of claim 3 for use in the treatment of a patient with a gastrointestinal disorder. The pharmaceutical composition of claim 5, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, constipation, gastrointestinal motility disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, gastroparesis, chronic small intestinal pseudo-obstruction and colonic pseudo-obstruction .7. The pharmaceutical composition of claim 6, wherein the gastrointestinal upset is constipation. The pharmaceutical composition of claim 7, wherein the constipation is chronic constipation, idiopathic constipation, constipation resulting from postoperative bowel obstruction, and constipation caused by the use of opiates. The pharmaceutical composition of claim 7, wherein constipation is chronic constipation. The pharmaceutical composition of claim 6, wherein the gastrointestinal upset is irritable bowel syndrome (IBS). The pharmaceutical composition of claim 10, wherein the gastrointestinal upset is constipated irritable bowel syndrome (c-IBS). The method of obtaining pep1. Пептид, состоящий из последовательности аминокислот CysCysGluTyrCysCysAsnProAlaCysThrGlyCysTyr, где дисульфидные связи присутствуют между Cys-Cys, Cys-Cysи Cys-Cys, или его фармацевтически приемлемая соль.2. П
